Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion
Standard
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion. / Garderet, Laurent; Ziagkos, Dimitris; van Biezen, Anja; Iacobelli, Simona; Finke, Jürgen; Maertens, Johan; Volin, Liisa; Ljungman, Per; Chevallier, Patrice; Passweg, Jakob; Schaap, Nicolaas; Beelen, Dietrich; Nagler, Arnon; Blaise, Didier; Poiré, Xavier; Yakoub-Agha, Ibrahim; Lenhoff, Stig; Craddock, Charles; Schots, Rik; Rambaldi, Alessandro; Sanz, Jaime; Jindra, Pavel; Mufti, Ghulam J; Robin, Marie; Kröger, Nicolaus.
In: BIOL BLOOD MARROW TR, Vol. 24, No. 3, 03.2018, p. 507-513.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion
AU - Garderet, Laurent
AU - Ziagkos, Dimitris
AU - van Biezen, Anja
AU - Iacobelli, Simona
AU - Finke, Jürgen
AU - Maertens, Johan
AU - Volin, Liisa
AU - Ljungman, Per
AU - Chevallier, Patrice
AU - Passweg, Jakob
AU - Schaap, Nicolaas
AU - Beelen, Dietrich
AU - Nagler, Arnon
AU - Blaise, Didier
AU - Poiré, Xavier
AU - Yakoub-Agha, Ibrahim
AU - Lenhoff, Stig
AU - Craddock, Charles
AU - Schots, Rik
AU - Rambaldi, Alessandro
AU - Sanz, Jaime
AU - Jindra, Pavel
AU - Mufti, Ghulam J
AU - Robin, Marie
AU - Kröger, Nicolaus
N1 - Copyright © 2017. Published by Elsevier Inc.
PY - 2018/3
Y1 - 2018/3
N2 - The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.
AB - The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.
KW - Journal Article
U2 - 10.1016/j.bbmt.2017.11.017
DO - 10.1016/j.bbmt.2017.11.017
M3 - SCORING: Journal article
C2 - 29196078
VL - 24
SP - 507
EP - 513
JO - BIOL BLOOD MARROW TR
JF - BIOL BLOOD MARROW TR
SN - 1083-8791
IS - 3
ER -